These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38311516)

  • 1. Hepatic cytoreduction for lung and renal neuroendocrine tumor metastases.
    Fowler K; Li J; Pommier RF
    Am J Surg; 2024 May; 231():41-45. PubMed ID: 38311516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
    Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
    Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
    Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors.
    Wonn SM; Limbach KE; Pommier SJ; Ratzlaff AN; Leon EJ; McCully BH; Pommier RF
    Surgery; 2021 Jan; 169(1):168-174. PubMed ID: 32473829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.
    Morgan RE; Pommier SJ; Pommier RF
    Surgery; 2018 Jan; 163(1):218-225. PubMed ID: 29103583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum.
    Gudmundsdottir H; Fogliati A; Grotz TE; Thiels CA; Warner SG; Smoot RL; Truty MJ; Kendrick ML; Nagorney DM; Halfdanarson TR; Cleary SP; Starlinger P
    Ann Surg Oncol; 2024 Aug; 31(8):5370-5376. PubMed ID: 38689169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
    Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic neuroendocrine metastases: does intervention alter outcomes?
    Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
    J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
    Hung JS; Chang MC; Lee PH; Tien YW
    World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
    Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
    Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.
    van Beek DJ; Nell S; Verkooijen HM; Borel Rinkes IHM; Valk GD; ; Vriens MR; ;
    Surgery; 2021 Apr; 169(4):963-973. PubMed ID: 33220975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical Management of Neuroendocrine Tumor Liver Metastases.
    Tran CG; Sherman SK; Chandrasekharan C; Howe JR
    Surg Oncol Clin N Am; 2021 Jan; 30(1):39-55. PubMed ID: 33220808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.
    Chakedis J; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Marincola-Smith P; Cho C; Beems M; Pawlik TM; Maithel SK; Schmidt CR; Dillhoff M
    J Gastrointest Surg; 2019 Jan; 23(1):122-134. PubMed ID: 30334178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.
    Woltering EA; Voros BA; Beyer DT; Wang YZ; Thiagarajan R; Ryan P; Wright A; Ramirez RA; Ricks MJ; Boudreaux JP
    J Am Coll Surg; 2017 Apr; 224(4):434-447. PubMed ID: 28088602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy.
    Ammann M; Gudmundsdottir H; Hackl H; Antwi SKA; Santol J; Habermann EB; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Nagorney DM; Cleary SP; Halfdanarson TR; Starlinger PP
    Ann Surg Oncol; 2024 Aug; 31(8):4931-4941. PubMed ID: 38717544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy.
    Maekawa A; Kudo A; Kishino M; Murase Y; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Ogawa K; Ono H; Tanaka S; Kinowaki Y; Tanabe M
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):697-706. PubMed ID: 33904982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
    Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
    JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.